Clinical trialsCompany release
Rejuvenate Biomed completes last patient visit in Phase 2 MINT-COPD trial of RJx-01
Rejuvenate Biomed NV · Mon 16 Nov 2026
The last participant has finished the final visit in the placebo-controlled study in older COPD patients, with topline data still expected by the end of 2026.
Rejuvenate Biomed announced on 16 November 2026 that the last patient has completed the final visit in MINT-COPD, its randomised, placebo-controlled Phase 2 trial of RJx-01.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release: Rejuvenate Biomed NV ↗
Article written by VigiEye from the official source (Rejuvenate Biomed NV). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Cerenome reports no dose-limiting toxicities in first 10 patients on repeat intraventricular REYOBIQ
🇺🇸 Cerenome, Inc. (CNSY) · Mon 16 Nov 2026
Clearmind completes Part C enrolment in CMND-100 alcohol use disorder trial
Clearmind Medicine Inc. (CMND) · Mon 16 Nov 2026
Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M
🇺🇸 Jasper Therapeutics, Inc. (JSPR) · Mon 16 Nov 2026
CG Oncology's cretostimogene meets Phase 3 PIVOT-006 endpoint in intermediate-risk bladder cancer
🇺🇸 CG Oncology, Inc. (CGON) · Mon 16 Nov 2026
Aptevo's mipletamig triplet yields 79% CR/CRi in TP53-mutated AML; infusion reactions fall
🇺🇸 Aptevo Therapeutics Inc. (APVO) · Mon 16 Nov 2026
Rein Therapeutics releases blinded Phase 2 RENEW lung function data for inhaled LTI-03 in IPF
🇺🇸 Rein Therapeutics, Inc. (RNTX) · Mon 16 Nov 2026